22.	Supplemental data

The following information is presented as supplemental data as required by the indentures governing the Company’s senior notes.

Condensed Consolidating Statements of Income

										Company and
	Consolidated			Physician			Unrestricted			Restricted
For the nine months ended September 30, 2016	Total			Groups			Subsidiaries			Subsidiaries⁽¹⁾
Patient service operating revenues	$	7,678,053		$	287,544		$	—		$	7,390,509
Less: Provision for uncollectible accounts		(336,188	)		(9,178	)		—			(327,010	)
Net patient service operating revenues		7,341,865			278,366			—			7,063,499
Capitated revenues		2,654,163			1,186,001			—			1,468,162
Other revenues		1,033,335			53,124			—			980,211
Total net operating revenues		11,029,363			1,517,491			—			9,511,872
Operating expenses		9,516,248			1,513,569			(129	)		8,002,808
Operating income		1,513,115			3,922			129			1,509,064
Debt expense, including refinancing charges		(310,359	)		(9,347	)		—			(301,012	)
Other income		8,067			322			—			7,745
Income tax expense		366,011			10,442			52			355,517
Net income (loss)		844,812			(15,545	)		77			860,280
Less: Net income attributable to noncontrolling interests		(122,664	)		—			—			(122,664	)
Net income (loss) attributable to DaVita Inc.	$	722,148		$	(15,545	)	$	77		$	737,616

⁽¹⁾	After elimination of the unrestricted subsidiaries and the physician groups.

Condensed Consolidating Statements of Comprehensive Income

									Company and
	Consolidated			Physician			Unrestricted		Restricted
For the nine months ended September 30, 2016	Total			Groups			Subsidiaries		Subsidiaries⁽¹⁾
Net income (loss)	$	844,812		$	(15,545	)	$	77	$	860,280
Other comprehensive loss		7,807			—			—		7,807
Total comprehensive income (loss)		852,619			(15,545	)		77		868,087
Less: comprehensive income attributable to the noncontrolling interests		(122,871	)		—			—		(122,871	)
Comprehensive income (loss) attributable to DaVita Inc.	$	729,748		$	(15,545	)	$	77	$	745,216

⁽¹⁾	After elimination of the unrestricted subsidiaries and the physician groups.

Condensed Consolidating Balance Sheets

							Company and
	Consolidated		Physician		Unrestricted		Restricted
As of September 30, 2016	Total		Groups		Subsidiaries		Subsidiaries⁽¹⁾
Cash and cash equivalents	$	913,496	$	104,636	$	—	$	808,860
Accounts receivable, net		1,850,425		195,488		—		1,654,937
Other current assets		1,497,438		18,419		—		1,479,019
Total current assets		4,261,359		318,543		—		3,942,816
Property and equipment, net		3,044,988		1,417		—		3,043,571
Amortizable intangibles, net		1,576,157		5,141		—		1,571,016
Other long-term assets		660,153		77,681		2,696		579,776
Goodwill		9,382,996		16,405		—		9,366,591
Total assets	$	18,925,653	$	419,187	$	2,696	$	18,503,770
Current liabilities	$	2,639,469	$	229,515	$	—	$	2,409,954
Payables to parent		—		86,335		2,696		(89,031	)
Long-term debt and other long-term liabilities		10,195,049		50,099		—		10,144,950
Noncontrolling interests subject to put provisions		971,744		—		—		971,744
Total DaVita Inc. shareholders’ equity		4,911,746		53,238		—		4,858,508
Noncontrolling interests not subject to put provisions		207,645		—		—		207,645
Shareholders’ equity		5,119,391		53,238		—		5,066,153
Total liabilities and shareholder’s equity	$	18,925,653	$	419,187	$	2,696	$	18,503,770

⁽¹⁾	After elimination of the unrestricted subsidiaries and the physician groups.

Condensed Consolidating Statements of Cash Flows

										Company and
	Consolidated			Physician			Unrestricted			Restricted
For the nine months ended September 30, 2016	Total			Groups			Subsidiaries			Subsidiaries⁽¹⁾
Cash flows from operating activities:
Net income (loss)	$	844,812		$	(15,545	)	$	77		$	860,280
Changes in operating and intercompany assets and liabilities and non-cash items included in net income		636,450			152,461			(77	)		484,066
Net cash provided by operating activities		1,481,262			136,916			—			1,344,346
Cash flows from investing activities:
Additions of property and equipment		(575,243	)		(592	)		—			(574,651	)
Acquisitions and divestitures, net		(497,331	)		—			—			(497,331	)
Proceeds from discontinued operations		18,991			—			—			18,991
Investments and other items		(203,659	)		(2,124	)		—			(201,535	)
Net cash used in investing activities		(1,257,242	)		(2,716	)		—			(1,254,526	)
Cash flows from financing activities:
Long-term debt		(98,724	)		(4	)		—			(98,720	)
Intercompany		—			(117,805	)		—			117,805
Other items		(709,252	)		—			—			(709,252	)
Net cash used in by financing activities		(807,976	)		(117,809	)		—			(690,167	)
Effect of exchange rate changes on cash		(1,664	)		—			—			(1,664	)
Net decrease in cash		(585,620	)		16,391			—			(602,011	)
Cash and cash equivalents at beginning of period		1,499,116			88,245			—			1,410,871
Cash and cash equivalents at end of period	$	913,496		$	104,636		$	—		$	808,860

⁽¹⁾	After elimination of the unrestricted subsidiaries and the physician groups.